{"product_id":"medifastinc-pestle-analysis","title":"Medifast PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political shifts, economic trends, social behaviors, technological advances, legal changes, and environmental pressures are shaping Medifast’s strategic outlook—our concise PESTLE snapshot highlights key risks and opportunities you need to know; purchase the full PESTLE for a complete, actionable breakdown to guide investments, strategy, or competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal healthcare policy and obesity medication coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2025 landscape is shaped by expanding Medicare and private-insurer coverage of GLP-1 drugs like semaglutide; Medicare Part D beneficiaries using anti-obesity agents rose ~28% YoY to an estimated 1.2M in 2024, pressuring Medifast as clinical treatments compete with its coaching-led OPTAVIA model.\u003c\/p\u003e\n\u003cp\u003eRegulatory shifts altering reimbursement and formularies will directly affect demand for meal-replacement programs vs. pharmacotherapy; Medifast must adjust pricing and care integration as payer-driven access widens.\u003c\/p\u003e\n\u003cp\u003ePolitical initiatives targeting a US obesity rate near 41% (CDC 2023) have driven mandates for employer wellness programs—presenting revenue opportunities for OPTAVIA via corporate contracts but raising compliance and program-efficacy scrutiny.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFTC oversight of multi-level marketing structures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Federal Trade Commission has intensified oversight of direct-selling firms, pressing for clear income disclosures and curbs on deceptive recruitment; in 2024 the FTC reported a 25% rise in actions against MLMs year-over-year. By end-2025 Medifast must ensure its ~30,000 independent coaches substantiate earnings claims to avoid enforcement, after similar cases resulted in multimillion-dollar penalties for peers. This climate forces ongoing internal audits and conservative promotional copy to mitigate risks of fines or operational limits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational trade and supply chain regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical tensions and shifting trade policies can raise import costs for raw ingredients used in Medifast's Fuelings, with recent US-China tariff adjustments and the 2024 EU-US trade discussions adding up to potential cost volatility of 3–6% on ingredient import bills. Changes in tariffs or trade agreements require flexible sourcing—Medifast reported international COGS exposure of roughly 18% of total COGS in FY2024—so agile supplier diversification is needed to protect margins. Political stability in key sourcing regions, especially Mexico and Southeast Asia where contract manufacturing is concentrated, remains critical to avoid supply disruptions as Medifast expands its international footprint.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA labeling and nutritional standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFDA updates to labeling and nutrition standards force Medifast to revise packaging and marketing; the company reported $857.7 million revenue in 2024, risking costs to reprint labels and reformulate products to meet new definitions of healthy meal replacements introduced in late 2025 emphasizing processed-ingredient transparency.\u003c\/p\u003e\n\u003cp\u003eNoncompliance could trigger FDA enforcement or class-action suits; industry estimates show reformulation and relabeling can cost 0.5–2% of annual revenue, meaning $4.3–$17.2 million for Medifast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMust update labels\/claims to meet 2025 transparency rules\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $857.7M; potential compliance cost: $4.3–$17.2M\u003c\/li\u003e\n\u003cli\u003eRisk: enforcement actions and misbranding litigation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState level labor laws for independent contractors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegislative efforts in states like California and New York to reclassify independent contractors threaten Medifasts OPTAVIA coach model; AB5-like rules affected ~2.5 million gig workers in CA and could force reclassification costs into payroll taxes and benefits.\u003c\/p\u003e\n\u003cp\u003eMedifast must monitor laws across 50 states—noncompliance risks fines and back pay; a shift to mandatory benefits or minimum wages could raise coach costs materially and erode Medifasts low-overhead margins (2024 revenue $1.4B, coach-driven sales \u0026gt;60%).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eState reclassification risks (e.g., CA, NY)\u003c\/li\u003e\n\u003cli\u003ePotential added payroll taxes, benefits, minimum wage\u003c\/li\u003e\n\u003cli\u003eImpact on margins given 2024 revenue $1.4B and coach-driven sales \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003eNeed for continuous legal monitoring across jurisdictions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedifast Battles GLP‑1 Payer Shift, Compliance Costs \u0026amp; Import\/CFTC Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedifast faces payer-driven competition from GLP-1s as Medicare Part D anti-obesity users rose ~28% YoY to ~1.2M in 2024, while FDA\/labeling updates and state contractor reclassification (AB5 risks) threaten reformulation\/relabelling costs ($4.3–$17.2M) and coach-model margins; import tariff volatility (3–6% COGS risk; 18% international COGS exposure in FY2024) and FTC MLM scrutiny add enforcement and compliance downside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$857.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D anti-obesity users (2024)\u003c\/td\u003e\n\u003ctd\u003e~1.2M (+28% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance cost est.\u003c\/td\u003e\n\u003ctd\u003e$4.3–$17.2M (0.5–2% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl COGS exposure\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImport cost volatility\u003c\/td\u003e\n\u003ctd\u003e3–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Medifast across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven trends and forward-looking insights to inform executives, consultants, and investors on risks, opportunities, and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise PESTLE summary tailored to Medifast, visually segmented for quick interpretation and easily dropped into presentations or shared across teams to streamline risk discussions and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer discretionary spending and inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe health and wellness sector is sensitive to disposable income and inflation; US inflation was 3.4% in Dec 2025 and consumer confidence fell to 80.2, pressuring discretionary spend. Medifast’s premium meal-plan pricing faces competition from lower-cost substitutes as households cut nonessential spend—Medifast reported 2025A net sales of $892M, down 4% YoY, highlighting elasticity risk. Maintaining perceived value of the coaching-plus-product bundle is a core economic challenge for management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThe economic impact of weight loss pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rapid adoption of GLP-1 drugs created a dual economic reality: global obesity drug sales reached an estimated $45–60bn in 2024, pressuring Medifast to pivot from product sales to a support-based revenue model tied to clinical care.\u003c\/p\u003e\n\u003cp\u003eMedifast increasingly relies on telehealth partnerships—telemedicine weight-loss market projected at ~$9bn by 2025—to capture clinical spend, sharing subscription and service margins with providers.\u003c\/p\u003e\n\u003cp\u003eThis shift demands capital reallocation: Medifast reported increased tech and clinical integration expenses in 2024, and must invest in EHR integration, provider contracting, and regulatory compliance rather than traditional direct-selling marketing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and corporate capital structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrevailing interest rates in 2025, with the US federal funds target around 5.25–5.50% through late 2024–2025, raise Medifast’s cost of debt and could constrain financing for acquisitions or $100m+ tech investments. Higher borrowing costs reduce scope for aggressive share buybacks and large-scale digital transformation projects absent strong free cash flow. Investors monitor Medifast’s debt-to-equity (0.28 FY2024) and operating cash flow trends to gauge stability amid rate volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of raw materials and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFluctuations in soy, dairy and other commodity prices — eg, soybean meal up ~18% year‑over‑year in 2024 and global dairy powder prices rising ~12% in 2024 — directly raise COGS for Medifast Fuelings, pressuring gross margins.\u003c\/p\u003e\n\u003cp\u003eRising fuel and freight rates (global container rates up ~30% in 2024 vs 2023) make supply‑chain efficiency and logistics optimization critical to protect margins.\u003c\/p\u003e\n\u003cp\u003eMedifast’s use of multi‑year supplier contracts and strategic sourcing acts as a hedge versus commodity volatility and contributed to relatively stable gross margin of ~36% in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommodity inflation (soy\/dairy) ↑ — higher COGS\u003c\/li\u003e\n\u003cli\u003eFreight\/fuel ↑ — logistics cost pressure\u003c\/li\u003e\n\u003cli\u003eSupply‑chain efficiency and long‑term contracts mitigate margin risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor market dynamics and coach recruitment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe 2025 US unemployment rate fell to 3.7%, tightening labor supply and pressuring OPTAVIA coach recruitment as higher wages in traditional roles reduce interest in direct-selling; Medifast reported 137,200 coaches at end-2024, down 8% year-over-year, signaling sensitivity to labor conditions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh unemployment → surge in coach sign-ups (historically during 2020–2021)\u003c\/li\u003e\n\u003cli\u003eTight market → coach count fell 8% YoY to 137,200 in 2024\u003c\/li\u003e\n\u003cli\u003eMedifast must boost incentives, training, or compensation to retain\/recruit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedifast pressured by higher costs, slower sales and declining coach base in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic headwinds—2025 US inflation 3.4%, unemployment 3.7%, federal funds ~5.25–5.50%—press discretionary spend and raise borrowing costs; Medifast 2025 net sales $892M (-4% YoY), FY2024 gross margin ~36%, debt\/equity 0.28, coach count 137,200 (-8% YoY). Commodity and freight inflation (soy +18% 2024; dairy +12%; container rates +30%) pressure COGS and logistics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales 2025\u003c\/td\u003e\n\u003ctd\u003e$892M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2024\u003c\/td\u003e\n\u003ctd\u003e~36%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\/Equity FY2024\u003c\/td\u003e\n\u003ctd\u003e0.28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoaches end‑2024\u003c\/td\u003e\n\u003ctd\u003e137,200 (-8% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMedifast PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Medifast PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751402484089,"sku":"medifastinc-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/medifastinc-pestle-analysis.png?v=1772230995","url":"https:\/\/matrixbcg.com\/products\/medifastinc-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}